Blood and Blood Products: CA – UnitedHealthcare West Benefit Interpretation Policy
Defines UnitedHealthcare West coverage and exclusions for use and administration of blood and blood components (e.g., cryoprecipitate, platelets, plasma, albumin, gamma globulin, fibrinogen, clotting factors) in inpatient and outpatient settings, including autologous/donor-directed processing costs and bloodless surgery with prior authorization. References member Evidence of Coverage for plan-specific provisions.
Routine review; no change to coverage guidelines.
Coverage Summary
This policy defines UnitedHealthcare West coverage and exclusions for the use and administration of blood and blood components (including but not limited to cryoprecipitate, platelets, fibrinogen, plasma, gamma globulin, albumin, and clotting factors) in both inpatient and outpatient settings. It also addresses autologous (self-donated) and donor-directed processing costs, coverage for blood collected but not used when authorized by a physician, and bloodless surgery (procedures without transfusions or blood products, including Rho(D) immune globulin) which requires medical necessity and prior authorization. Refer to the member's Evidence of Coverage (EOC)/Schedule of Benefits (SOB) for plan-specific limitations and provisions. State and federal mandated regulations and state market plan enhancements: None.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.